University of Nebraska

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, University of Nebraska sits in the top decile of US sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count).

407 total trials 51 currently recruiting 261 completed early-phase tilt top decile by trial count

University of Nebraska: 407 sponsored US clinical trials, 51 recruiting.

University of Nebraska sponsors 407 registered US clinical trials on ClinicalTrials.gov, 51 of them currently recruiting, and 261 completed. 31 of these trials are in Phase 3-4 (later-stage) and 109 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Peripheral Arterial Disease, with 7 trials.

Top-decile sponsor footprint

University of Nebraska ranks in the top decile of sponsors by registered trial count (#90 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 36/100

261 of 332 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

407 total, page 6 of 9

COMPLETED

Echo Detection of Endoscopic Retrograde Cholangiopancreatography (ERCP) Air Embolus

NCT01535248

COMPLETED

Use of Strattice Mesh in Paraesophageal Hernia Surgery

NCT01678157

COMPLETED NA

Effect of Mobile Phone Telemedicine on Diabetes Care

NCT01698008

COMPLETED NA

Serum 25-hydroxy Vitamin D [25(OH)D] Levels, Supplemental Vitamin D, and Parathyroid Hormone Levels in Premature Infants

NCT01469650

TERMINATED NA

Diaphragmatic Breathing Retraining in Heart Failure Patients: Health-Behavior Related Outcomes

NCT01478932

COMPLETED NA

The Role of Vitamin D in Chronic Urticaria and Angioedema Treatment

NCT01371877

TERMINATED

Sulfation of Bile Acids as a Biomarker for Hepatobiliary Diseases

NCT01200082

COMPLETED

Biomarkers for Prognosis of Glioblastoma (GBM)

NCT01493219

COMPLETED Phase 2

Ruxolitinib Phosphate to Treat Diffuse Large B-Cell or Peripheral T-Cell Non-Hodgkin Lymphoma After Stem Cell Transplant

NCT01431209

TERMINATED

First-Sight Refractive Error Correction: Direct Comparison to Autorefraction Results in Children 7 to 18 Years of Age

NCT01365884

COMPLETED Phase 2

Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

NCT01336933

COMPLETED

Rapid 10-Minute Liver MRI Protocol in Patients With Suspected Hepatocellular Carcinoma

NCT01390194

COMPLETED Phase 1

Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

NCT01336920

COMPLETED NA

Web-Based Weight Loss & Weight Maintenance Intervention for Older Rural Women, Also Known as Women Weigh-in for Wellness

NCT01307644

COMPLETED

Stem Cells Predicting Orthopedic Outcomes

NCT01366911

COMPLETED

Proof of Concept Study for First-Sight Refractive Error Correction: Direct Comparison to Manifest Refraction and Autorefraction Results

NCT01342393

COMPLETED NA

Physical Activity Telehealth Intervention After Percutaneous Coronary Procedures

NCT01673100

TERMINATED Phase 2

Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer

NCT01307956

COMPLETED NA

Impact of a High-fat Meal on Assessment of Clopidogrel-induced Platelet Inhibition in Healthy Subjects

NCT01307657

COMPLETED

IOP Lowering Effects of Topical Anesthetics Used Frequently in the Ophthalmology Clinic

NCT01254149

COMPLETED

Awakening-Breathing Coordination, Delirium Monitoring/Management & Early Mobility (ABCDE) Protocol

NCT01413009

COMPLETED

Pilot Testing a New Computer-based Screening Tool to Detect Cognitive Impairment

NCT01220674

COMPLETED

Effect of Rosuvastatin Response in Healthy Subjects: Potential Mechanisms of Anti-inflammatory Effects

NCT00874757

COMPLETED NA

Measurement of Plasma and Intracellular Concentrations of Raltegravir

NCT01214486

COMPLETED Phase 1

Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors

NCT01206465

COMPLETED NA

Mechanisms That Produce the Leg Dysfunction of Claudication & Treatment Strategies

NCT01970332

COMPLETED

Effects of Selective Laser Trabeculoplasty on Aqueous Humor Dynamics

NCT01342406

COMPLETED Phase 1

Interventions to Decrease the Impact of Post-OPerative Ileus After Liver Transplant or Resection Surgery

NCT01156129

COMPLETED

Chronic HIV Infection and Aging in NeuroAIDS (CHAIN)

NCT01186042

COMPLETED Early Phase 1

Aqueous Humor Dynamics and Brimonidine

NCT01144494

COMPLETED NA

Echocardiography Management for Patients Requiring Care for Non-Cardiac Surgery

NCT01050361

COMPLETED

Periodontal Disease and P. Gingivalis in Rheumatoid Arthritis

NCT01156155

COMPLETED

The Midwest Head and Neck Cancer Consortium Multi-Institutional Parathyroid Registry

NCT01409798

COMPLETED NA

Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM)

NCT01163968

COMPLETED

Impact of Race/Ethnicity on Platelet Function

NCT01168622

COMPLETED NA

Diode Laser Study for Periodontal Maintenance Patients

NCT01215201

COMPLETED Phase 1

Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT01060384

COMPLETED Phase 2

Cyclophosphamide and Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Who Have Undergone Surgery

NCT01106898

TERMINATED Phase 4

Melatonin CR for the Treatment of Impaired Sleep Maintenance in 4-8 Year Old Children With Autism Spectrum Disorders

NCT01033565

TERMINATED Phase 1

Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

NCT01093183

COMPLETED NA

Developing Genetic Education for Smoking Cessation

NCT01186016

TERMINATED NA

Abdominal MR Imaging at 3.0T: Sequence Optimization and Implementation

NCT01007357

TERMINATED Phase 2

Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

NCT01044745

COMPLETED Phase 1

Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma

NCT01035463

COMPLETED NA

Wii-Fit For Improving Activity, Gait And Balance In Alzheimer's Dementia

NCT01002586

COMPLETED NA

Alcohol Exposure and Airway Hyperresponsiveness

NCT00990275

TERMINATED NA

Herbal Lollipops on Oral Bacterial Levels and DMFT/Dmft Scores of Children With Asthma Using Inhalers

NCT01147835

COMPLETED

Vitamin D Levels in Subjects With Chronic Urticaria and Angioedema

NCT00876369

COMPLETED

Continuous Hemoglobin Monitoring in Pediatric Transplant

NCT00958984

COMPLETED NA

Vitamin D Status and Dose Response in Infants

NCT01042561

← Previous Page 6 of 9 Next →

Phase Distribution

PhaseTrial count
Phase 1 57
Phase 2 52
Phase 3 10
Phase 4 21

What is open in the University of Nebraska pipeline

51 recruiting of 407 indexed (13% open); 261 completed (64%).

Phase mix: 31 late (III/IV) vs 109 early (I/II) (early-phase heavy).

Top condition: Peripheral Arterial Disease (7 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

University of Nebraska: open-pipeline peers nationwide

Peers matched on 407 registered trials and 13% open enrollment, not the therapeutic-area sidebar.

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0100200300400500 10%15%20%25% Total trials Recruiting share University of NebraskaCase Comprehensive Cancer CenterTakedaUniversity of Kansas Medical CenterSt. Jude Children's Research HospitalAddario Lung Cancer Medical InstituteAmerican UniversityAnnexonAnsun Biopharma
University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

University of Nebraska sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 407 trials (± recruiting share)

Sponsors near 13% open enrollment (± trial volume)

What to do with this University of Nebraska page

407 registered trials is a research-attention snapshot, not an endorsement of University of Nebraska or any single study.

  • 51 of University of Nebraska's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Peripheral Arterial Disease is the condition University of Nebraska studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Peripheral Arterial Disease trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

University of Nebraska pipeline card: 407 registered trials from official public datasets.Report a data error.